Cargando…
Risk of Cancer among Commercially Insured HIV-Infected Adults on Antiretroviral Therapy
The objective of this study was to explore the cancer incidence rates among HIV-infected persons with commercial insurance who were on antiretroviral therapy and compare them with those rates in the general population. Paid health insurance claims for 63,221 individuals 18 years or older, with at le...
Autores principales: | Lee, Jeannette Y., Dhakal, Ishwori, Casper, Corey, Noy, Ariela, Palefsky, Joel M., Haigentz, Missak, Krown, Susan E., Ambinder, Richard F., Mitsuyasu, Ronald T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5110893/ https://www.ncbi.nlm.nih.gov/pubmed/27882054 http://dx.doi.org/10.1155/2016/2138259 |
Ejemplares similares
-
Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management
por: Abdullah, Shaad E., et al.
Publicado: (2012) -
EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012) -
Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in human immunodeficiency virus-associated, B-cell non-Hodgkin lymphoma
por: Sparano, Joseph A., et al.
Publicado: (2020) -
Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors
por: Saba, Nabil F., et al.
Publicado: (2012) -
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin’s Lymphoma (AMC-075)
por: Ramos, Juan C., et al.
Publicado: (2018)